Uroexam spol. s r.o.

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Prostate cancer6 trials

Phase

• Phase 35 trials
• Phase 21 trial

Status

• Active, not recruiting4 trials
• Recruiting2 trials

Lead sponsor

• Astellas Pharma Global Development, Inc.1 trial
• AstraZeneca1 trial
• Janssen Pharmaceutica N.V., Belgium1 trial
• Merck Sharp & Dohme LLC1 trial
• Novartis Pharmaceuticals1 trial
• and 1 more

Running trials

• Recruiting

  An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

  NCT05939414· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

  NCT06136650· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer

  NCT04557059· Phase 3· Janssen Pharmaceutica N.V., Belgium· Source

• Active, not recruiting

  Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

  NCT04493853· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

  NCT02960022· Phase 2· Astellas Pharma Global Development, Inc.· Source

• Active, not recruiting

  Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

  NCT02319837· Phase 3· Pfizer· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer2 recruiting